Question: why is nektar therapeutics down?
Answer: Shares of Nektar Therapeutics crashed 39% on Friday morning after the biopharmaceutical company divulged a quality-control issue with a key cancer therapy. The drug, which is called Bempegaldesleukin and intended to treat melanoma and other cancers, is still in the development and trial stages.